[1]CurrentPatentAssignee:HEFEIHUAFANGPHARMACEUTICALSCIENCESTECHNOLOGY-CN105693805,2016,ALocationinpatent:Paragraph0040;0041;0042
[1]CurrentPatentAssignee:SHAANXISYNTHETICPHARMACEUTICAL-CN106478759,2017,ALocationinpatent:Paragraph0030;0031
Title: Yangonin protects against cholestasis and hepatotoxity via activation of farnesoid X receptor in vivo and in vitro.
Journal: Toxicology and applied pharmacology 20180601
Title: Steviol, an aglycone of steviol glycoside sweeteners, interacts with the pregnane X (PXR) and aryl hydrocarbon (AHR) receptors in detoxification regulation.
Journal: Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20171101
Title: Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system.
Journal: Toxicology in vitro : an international journal published in association with BIBRA 20170301
Title: Dihydroartemisinin protects against alcoholic liver injury through alleviating hepatocyte steatosis in a farnesoid X receptor-dependent manner.
Journal: Toxicology and applied pharmacology 20170115
Title: Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor.
Journal: Toxicology letters 20170104
Title: Obeticholic acid protects against carbon tetrachloride-induced acute liver injury and inflammation.
Journal: Toxicology and applied pharmacology 20170101
Title: Pyrazinamide Induced Rat Cholestatic Liver Injury through Inhibition of FXR Regulatory Effect on Bile Acid Synthesis and Transport.
Journal: Toxicological sciences : an official journal of the Society of Toxicology 20160801
Title: Obeticholic Acid: First Global Approval.
Journal: Drugs 20160801
Title: Farnesoid X Receptor Protects against Kidney Injury in Uninephrectomized Obese Mice.
Journal: The Journal of biological chemistry 20160129
Title: Synthetic farnesoid X receptor agonists induce high-density lipoprotein-mediated transhepatic cholesterol efflux in mice and monkeys and prevent atherosclerosis in cholesteryl ester transfer protein transgenic low-density lipoprotein receptor (-/-) mice.
Journal: The Journal of pharmacology and experimental therapeutics 20121201
Title: An improved synthesis of 6α-ethylchenodeoxycholic acid (6ECDCA), a potent and selective agonist for the Farnesoid X Receptor (FXR).
Journal: Steroids 20121101
Title: Testosterone and farnesoid X receptor agonist INT-747 counteract high fat diet-induced bladder alterations in a rabbit model of metabolic syndrome.
Journal: The Journal of steroid biochemistry and molecular biology 20121001
Title: Glucocorticoid receptor mediates the gluconeogenic activity of the farnesoid X receptor in the fasting condition.
Journal: FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20120701
Title: Conicasterol E, a small heterodimer partner sparing farnesoid X receptor modulator endowed with a pregnane X receptor agonistic activity, from the marine sponge Theonella swinhoei.
Journal: Journal of medicinal chemistry 20120112
Title: Testosterone protects from metabolic syndrome-associated prostate inflammation: an experimental study in rabbit.
Journal: The Journal of endocrinology 20120101
Title: FXR protects lung from lipopolysaccharide-induced acute injury.
Journal: Molecular endocrinology (Baltimore, Md.) 20120101
Title: Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA.
Journal: Mini reviews in medicinal chemistry 20110801
Title: Farnesoid X receptor agonists for primary biliary cirrhosis.
Journal: Current opinion in gastroenterology 20110501
Title: Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease.
Journal: Gut 20110401
Title: Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.
Journal: Bioorganic & medicinal chemistry letters 20100815
Title: Farnesoid X receptor activation prevents the development of vascular calcification in ApoE-/- mice with chronic kidney disease.
Journal: Circulation research 20100625
Title: Pharmacotherapy of cholestatic liver diseases.
Journal: Journal of digestive diseases 20100601
Title: FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats.
Journal: Journal of lipid research 20100401
Title: Discovery of 6alpha-ethyl-23(S)-methylcholic acid (S-EMCA, INT-777) as a potent and selective agonist for the TGR5 receptor, a novel target for diabesity.
Journal: Journal of medicinal chemistry 20091224
Title: The farnesoid X receptor modulates renal lipid metabolism and diet-induced renal inflammation, fibrosis, and proteinuria.
Journal: American journal of physiology. Renal physiology 20091201
Title: Farnesoid x receptor ligands inhibit vascular smooth muscle cell inflammation and migration.
Journal: Arteriosclerosis, thrombosis, and vascular biology 20071201
Title: Nongenomic actions of bile acids. Synthesis and preliminary characterization of 23- and 6,23-alkyl-substituted bile acid derivatives as selective modulators for the G-protein coupled receptor TGR5.
Journal: Journal of medicinal chemistry 20070906
Title: The farnesoid X receptor FXRalpha/NR1H4 acquired ligand specificity for bile salts late in vertebrate evolution.
Journal: American journal of physiology. Regulatory, integrative and comparative physiology 20070901
Title: The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo.
Journal: Molecular pharmacology 20061001
Title: Back door modulation of the farnesoid X receptor: design, synthesis, and biological evaluation of a series of side chain modified chenodeoxycholic acid derivatives.
Journal: Journal of medicinal chemistry 20060713
Title: Nuclear receptors, bile-acid detoxification, and cholestasis.
Journal: Lancet (London, England) 20060211
Title: Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis.
Journal: The Journal of pharmacology and experimental therapeutics 20051001
Title: A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.
Journal: The Journal of pharmacology and experimental therapeutics 20050801
Title: The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes.
Journal: Molecular pharmacology 20050801
Title: Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis.
Journal: The Journal of pharmacology and experimental therapeutics 20050501
Title: The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis.
Journal: Gastroenterology 20041101
Title: The farnesoid X receptor: a novel drug target?
Journal: Expert opinion on investigational drugs 20040901
Title: Bile acid derivatives as ligands of the farnesoid X receptor. Synthesis, evaluation, and structure-activity relationship of a series of body and side chain modified analogues of chenodeoxycholic acid.
Journal: Journal of medicinal chemistry 20040826
Title: Binding mode of 6ECDCA, a potent bile acid agonist of the farnesoid X receptor (FXR).
Journal: Bioorganic & medicinal chemistry letters 20030602
Title: 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
Journal: Journal of medicinal chemistry 20020815
Title: Nuclear receptors and lipid physiology: opening the X-files.
Journal: Science (New York, N.Y.) 20011130
Title: Identification of a nuclear receptor for bile acids.
Journal: Science (New York, N.Y.) 19990521
Title: Pellicciari R, et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem. 2002 Aug 15;45(17):3569-72.
Title: Fiorucci S, et al. Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther. 2005 May;313(2):604-12.
Title: Ghebremariam YT, et al. FXR agonist INT-747 upregulates DDAH expression and enhances sensitivity in high-salt fed Dahl rats. PLoS One. 2013 Apr 4;8(4):e60653.
Title: Verbeke L, et al. The FXR Agonist Obeticholic Acid Prevents Gut Barrier Dysfunction and Bacterial Translocation in Cholestatic Rats. Am J Pathol. 2015 Feb;185(2):409-19.
